A pilot study of standard-dose rituximab, ifosfamide, carboplatin and etoposide (RICE) plus bortezomib (Velcade) in a dose-escalating fashion for patients with relapsed or primary refractory aggressive B-cell non-Hodgkin's lymphoma who are candidates for autologous stem cell transplant.

Trial Profile

A pilot study of standard-dose rituximab, ifosfamide, carboplatin and etoposide (RICE) plus bortezomib (Velcade) in a dose-escalating fashion for patients with relapsed or primary refractory aggressive B-cell non-Hodgkin's lymphoma who are candidates for autologous stem cell transplant.

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 11 Apr 2012

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2012 Actual patient number is 7 as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top